PR Friend Press Releases

RemedyMD’s solution shifts focus towards research based on more comprehensive scientific evidence

Salt Lake City, US -January 25, 2010 — RemedyMD , the leading provider of Disease Registry software, today announced the first nationwide Multi-level Intervention Registry. The new registry was developed to help clinicians and researchers identify which interventions are most appropriate for specific patient populations.

Details about the registry: http://www.remedymd.com/cer100/multi_intervention.html

RemedyMD’s multi-level intervention registry compares the effectiveness of interventions:

* community-based multi-level interventions
* simple health education
* usual care

to reduce health disparities in cardiovascular disease, diabetes, cancer, musculoskeletal diseases, and birth outcomes. The registry includes all of the applications, data infrastructure, and tools that clinicians and researchers need to gather, synthesize and analyze both phenotypic and genotypic data simultaneously.

“Our experience has shown when you view and report across all data types at the same time, you discover patterns and associations that are indistinguishable using traditional methodologies” said Gary D. Kennedy, Founder and CEO of RemedyMD.

RemedyMD’s new multi-intervention registry includes a comprehensive set of electronic data collection (EDC) forms that are specific to this research, ad hoc reporting capability, and pattern recognition tools that assist users in identifying the most effective treatment options.

In support of this initiative RemedyMD is seeking additional partners who have existing data that addresses the specific needs of interventional researchers. All institutions involved in comparative effectiveness research that are planning on submitting grant proposals for AHRQ funding are invited to visit: http://www.remedymd.com/cer100/multi_intervention.html

RemedyMD Resources:
Resource Kit for Comparative Effectiveness Research: www.remedymd.com/cer_kit.html

Ways to Leverage Pediatric Diabetes Registry: http://www.remedymd.com/cer100/multi_intervention.html

Comparative Effectiveness Research: www.remedymd.com/cer_home.html

Disease Registry Software: www.remedymd.com/registries_home.html

About RemedyMD
RemedyMD® is the leading provider of specialized software applications, tools, and data necessary for comparative effectiveness research with more than 100 pre-built clinical, disease, and patient registry software applications. RemedyMD solutions are personalized to the institution, the clinical specialty, and to the individual provider’s preferences enabling researchers to identify new patterns, facilitate new discoveries, and improve medical outcomes. For more information, visit www.RemedyMD.com.

Press Contact:
Lane Peterson
RemedyMD
SALT LAKE CITY, US
801.733.3383
lpeterson@remedymd.com

http://www.RemedyMD.com

RemedyMD’s solution addresses Institute of Medicine’s top 100 priorities and shifts focus towards research based on more comprehensive scientific evidence

SALT LAKE CITY, US – November 14, 2009 — RemedyMD, the leading provider of Disease Registry Software, today announced the first nationwide renal replacement therapies registry. The new registry was developed to help clinicians and researchers identify which interventions are most appropriate for specific patient populations.

Details about the registry: http://www.remedymd.com/cer100/renal_therapies.html

Aligned with the Institute of Medicine’s Top 100 Priorities for Comparative Effectiveness Research(CER), RemedyMD’s renal therapies registry compares the effectiveness (including survival, hospitalization, quality of life, and costs) of renal replacement therapies including:
* Daily home hemodialysis
* Intermittent home hemodialysis
* Conventional in-center dialysis
* Continuous ambulatory peritoneal dialysis
* Renal transplantation
for patients of different ages, races, and ethnicities. The registry includes all of the applications, data infrastructure, and tools that clinicians and researchers need to gather, synthesize and analyze both phenotypic and genotypic data simultaneously.

“Our experience has shown when you view and report across all data types at the same time, you discover patterns and associations that are indistinguishable using traditional methodologies” said Gary D. Kennedy, Founder and CEO of RemedyMD.

RemedyMD’s new renal therapies registry includes a comprehensive set of electronic data collection (EDC) forms that are specific to kidney research, ad hoc reporting capability, and pattern recognition tools that assist users in identifying the most effective treatment options.

In support of this initiative RemedyMD is seeking additional partners who have existing data that addresses the specific needs of kidney researchers. All institutions involved in comparative effectiveness research that are planning on submitting grant proposals for AHRQ funding are invited to visit: http://www.remedymd.com/cer100/renal_therapies.html

RemedyMD Resources:
Resource Kit for Comparative Effectiveness Research: www.remedymd.com/cer_kit

Ways to leverage Renal Therapies Registry: www.remedymd.com/cer100/renal therapies

Comparative Effectiveness Research: www.remedymd.com/cer_home

Disease Registry Software: www.remedymd.com/registries_home

Institute of Medicine’s Top 100 Priorities for CER: www.remedymd.com/cer_kit

About RemedyMD
RemedyMD® is the leading provider of specialized software applications, tools, and data necessary for comparative effectiveness research with more than 100 pre-built clinical, disease, and patient registry software applications. RemedyMD solutions are personalized to the institution, the clinical specialty, and to the individual provider’s preferences enabling researchers to identify new patterns, facilitate new discoveries, and improve medical outcomes. For more information, visit www.RemedyMD.com.

PR Distributed by KJ Public Relations

Press Contact:
Lane Peterson
RemedyMD
SALT LAKE CITY, US
801.733.3383
lpeterson@remedymd.com

http://www.RemedyMD.com

RemedyMD’s solution addresses Institute of Medicine’s top 100 priorities and shifts focus towards research based on more comprehensive scientific evidence

SALT LAKE CITY, US – November 05, 2009 — RemedyMD , the leading provider of Disease Registry Software, today announced the first nationwide lower back pain registry to help clinicians and researchers identify which interventions are most appropriate for specific patient populations.

Details about the registry: www.remedymd.com/cer100/lower_back.html

Aligned with the Institute of Medicine’s Top 100 Priorities for Comparative Effectiveness Research (CER), RemedyMD’s lower back pain registry tracks the effectiveness of treatment strategies for low back pain without neurological deficit or spinal deformity. The registry includes all of the applications, data infrastructure, and tools that clinicians and researchers need to gather, synthesize and analyze both phenotypic and genotypic data simultaneously.

“Our experience has shown when researchers view and report across all data types at the same time, they discover patterns and associations that are indistinguishable using traditional methodologies” said Gary D. Kennedy, Founder and CEO of RemedyMD.

RemedyMD’s new Lower Back Pain Registry includes a comprehensive set of electronic data collection (EDC) forms that are specific to lower back pain research, ad hoc reporting capability, and pattern recognition tools that assist users in identifying the most effective treatment options.

In support of this initiative RemedyMD is seeking additional partners who have existing data that addresses the specific needs of lower back pain researchers. All institutions involved in comparative effectiveness research that are planning on submitting grant proposals for AHRQ funding are invited to visit: www.remedymd.com/cer100/lower_back

RemedyMD Resources:
Resource Kit for Comparative Effectiveness Research: www.remedymd.com/cer_kit
Ways to leverage Lower Back Pain Registry: www.remedymd.com/cer100/lower_back
Comparative Effectiveness Research: www.remedymd.com/cer_home
Disease Registry Software: www.remedymd.com/registries_home
Institute of Medicine’s Top 100 Priorities for CER: www.remedymd.com/cer_kit

About RemedyMD
RemedyMD® is the leading provider of specialized software applications, tools, and data necessary for comparative effectiveness research with more than 100 pre-built clinical, disease, and patient registry software applications. RemedyMD solutions are personalized to the institution, the clinical specialty, and to the individual provider’s preferences enabling researchers to identify new patterns, facilitate new discoveries, and improve medical outcomes. For more information, visit www.RemedyMD.com.

Press Contact:
Lane Peterson
RemedyMD
SALT LAKE CITY, US
801.733.3383
lpeterson@remedymd.com

http://www.RemedyMD.com

RemedyMD’s solution addresses Institute of Medicine’s top 100 priorities and shifts focus towards research based on more comprehensive scientific evidence

SALT LAKE CITY, US,November 04, 2009 — RemedyMD , the leading provider of Disease Registry Software, today announced the first nationwide neonatal registry to help clinicians and researchers identify which interventions are most appropriate for specific patient populations.

Details about the registry: www.remedymd.com/cer100/neonatal.html

Aligned with the Institute of Medicine’s Top 100 Priorities for Comparative Effectiveness Research (CER), RemedyMD’s neonatal registry compares the effectiveness of diverse models of comprehensive support services for infants and their families following discharge from a neonatal intensive care unit. The registry includes all of the applications, data infrastructure, and tools that clinicians and researchers need to gather, synthesize and analyze both phenotypic and genotypic data simultaneously.

“Our experience has shown when researchers view and report across all data types at the same time, they discover patterns and associations that are indistinguishable using traditional methodologies” said Gary D. Kennedy, Founder and CEO of RemedyMD.

RemedyMD’s new neonatal registry includes a comprehensive set of electronic data collection (EDC) forms that are specific to neonatal research, ad hoc reporting capability, and pattern recognition tools that assist users in identifying the most effective treatment options.

In support of this initiative RemedyMD is seeking additional partners who have existing data that addresses the specific needs of neonatal researchers. All institutions involved in comparative effectiveness research that are planning on submitting grant proposals for AHRQ funding are invited to visit: www.remedymd.com/cer100/neonatal

RemedyMD Resources:
Resource Kit for Comparative Effectiveness Research: www.remedymd.com/cer_kit
Ways to leverage Neonatal Registry: www.remedymd.com/cer100/neonatal
Comparative Effectiveness Research: www.remedymd.com/cer_home
Disease Registry Software: www.remedymd.com/registries_home
Institute of Medicine’s Top 100 Priorities for CER: www.remedymd.com/cer_kit

About RemedyMD
RemedyMD® is the leading provider of specialized software applications, tools, and data necessary for comparative effectiveness research with more than 100 pre-built clinical, disease, and patient registry software applications. RemedyMD solutions are personalized to the institution, the clinical specialty, and to the individual provider’s preferences enabling researchers to identify new patterns, facilitate new discoveries, and improve medical outcomes. For more information, visit www.RemedyMD.com.

Press Contact:
Lane Peterson
RemedyMD
SALT LAKE CITY, US
801.733.3383
lpeterson@remedymd.com

http://www.RemedyMD.com

RemedyMD’s solution addresses Institute of Medicine’s top 100 priorities and shifts focus towards research based on more comprehensive scientific evidence

SALT LAKE CITY, USA, November 03, 2009 — RemedyMD, the leading provider of Disease Registry Software, today announced the first nationwide cervical pain registry to help clinicians and researchers identify which interventions are most appropriate for specific patient populations

Details about the registry: www.remedymd.com/cer100/cerv.html

Aligned with the Institute of Medicine’s Top 100 Priorities for Comparative Effectiveness Research (CER), RemedyMD’s cervical pain registry tracks the effectiveness of combining physical therapy with various treatment strategies including:

*Artificial cervical discs
*Spinal fusion
*Pharmacologic treatment

for cervical disc and neck pain. The registry includes all of the applications, data infrastructure, and tools that clinicians and researchers need to gather, synthesize and analyze both phenotypic and genotypic data simultaneously.

“Our experience has shown when researchers view and report across all data types at the same time, they discover patterns and associations that are indistinguishable using traditional methodologies” said Gary D. Kennedy, Founder and CEO of RemedyMD.

RemedyMD’s new cervical pain registry includes a comprehensive set of electronic data collection (EDC) forms that are specific to cervical pain research, ad hoc reporting capability, and pattern recognition tools that assist users in identifying the most effective treatment options.

In support of this initiative RemedyMD is seeking additional partners who have existing data that addresses the specific needs of cervical pain researchers. All institutions involved in comparative effectiveness research that are planning on submitting grant proposals for AHRQ funding are invited to visit: www.remedymd.com/cer100/cerv

RemedyMD Resources:
Resource Kit for Comparative Effectiveness Research: www.remedymd.com/cer_kit
Ways to leverage Cervical Pain Registry: www.remedymd.com/cer100/cerv
Comparative Effectiveness Research: www.remedymd.com/cer_home
Disease Registry Software: www.remedymd.com/registries_home
Institute of Medicine’s Top 100 Priorities for CER: www.remedymd.com/cer_kit

About RemedyMD
RemedyMD® is the leading provider of specialized software applications, tools, and data necessary for comparative effectiveness research with more than 100 pre-built clinical, disease, and patient registry software applications. RemedyMD solutions are personalized to the institution, the clinical specialty, and to the individual provider’s preferences enabling researchers to identify new patterns, facilitate new discoveries, and improve medical outcomes. For more information, visit www.RemedyMD.com.

Press Contact:
Lane Peterson
RemedyMD
SALT LAKE CITY, US
801.733.3383
lpeterson@remedymd.com

http://www.RemedyMD.com

RemedyMD’s solution addresses Institute of Medicine’s top 100 priorities and shifts focus towards research based on more comprehensive scientific evidence

SALT LAKE CITY, US, October 28, 2009 — RemedyMD , the leading provider of Patient Registry Software, today announced the first nationwide Prostate Cancer registry to help clinicians and researchers identify which interventions are most appropriate for specific patient populations.

Details about the registry: www.remedymd.com/cer100/prostate.html

Aligned with the Institute of Medicine’s Top 100 Priorities for Comparative Effectiveness Research (CER), RemedyMD’s Prostate Cancer Registry tracks the survival, recurrence, side effects, longitudinal quality of life, and cost of various management strategies for localized prostate cancer including:

Active surveillance
Radical prostatectomy (conventional, robotic, and laparoscopic)
Radiotherapy (conformal, brachytherapy, proton-beam, and intensity-modulated radiotherapy)

The prostate cancer registry includes all of the applications, data infrastructure, and tools that clinicians and researchers need to gather, synthesize and analyze both phenotypic and genotypic data simultaneously.

“Our experience has shown when you view and report across all data types at the same time, you discover patterns and associations that are indistinguishable using traditional methodologies” said Gary D. Kennedy, Founder and CEO of RemedyMD.

RemedyMD’s new prostate cancer registry includes a comprehensive set of electronic data collection (EDC) forms that are specific to prostate cancer research, ad hoc reporting capability, and pattern recognition tools that assist users in identifying the most effective treatment options.

In support of this initiative RemedyMD is seeking additional partners who have existing data that addresses the specific needs of prostate cancer researchers. All institutions involved in comparative effectiveness research that are planning on submitting grant proposals for AHRQ funding are invited to visit: www.remedymd.com/cer100/prostate.html

RemedyMD Resources:
Resource Kit for Comparative Effectiveness Research: www.remedymd.com/cer_kit.html

Ways to leverage prostate cancer registry: www.remedymd.com/CER100/prostate.html

Comparative Effectiveness Research:
www.remedymd.com/cer_home.html

Disease Registry Software:
www.remedymd.com/registries_home.html

Institute of Medicine’s Top 100 Priorities for CER:
www.remedymd.com/cer_kit.html

About RemedyMD
RemedyMD® is the leading provider of specialized software applications, tools, and data necessary for comparative effectiveness research with more than 100 pre-built clinical, patient, and disease registry software applications. RemedyMD solutions are personalized to the institution, the clinical specialty, and to the individual provider’s preferences enabling researchers to identify new patterns, facilitate new discoveries, and improve medical outcomes. For more information, visit www.RemedyMD.com.

Press Contact:
Lane Peterson
RemedyMD
SALT LAKE CITY, US
801.733.3383
lpeterson@remedymd.com

http://www.RemedyMD.com

RemedyMD’s solution addresses Institute of Medicine’s top 100 priorities and shifts focus towards research based on more comprehensive scientific evidence

SALT LAKE CITY, US , October 26, 2009 — RemedyMD, the leading provider of disease registry software, today announced the first nationwide pediatric obesity registry to help clinicians and researchers identify which interventions are most appropriate for specific patient populations.

Details about the registry: www.remedymd.com/cer100/pediatric_obesity.html

Aligned with the Institute of Medicine’s Top 100 Priorities for Comparative Effectiveness Research (CER), RemedyMD’s pediatric obesity registry compares the effectiveness of school-based interventions involving meal programs, vending machines, and physical education, at different levels of intensity, in preventing and treating overweight and obese children and adolescents. The registry includes all of the applications, data infrastructure, and tools that clinicians and researchers need to gather, synthesize and analyze both phenotypic and genotypic data simultaneously.

“Our experience has shown when you view and report across all data types at the same time, you discover patterns and associations that are indistinguishable using traditional methodologies” said Gary D. Kennedy, Founder and CEO of RemedyMD.

RemedyMD’s new pediatric obesity registry includes a comprehensive set of electronic data collection (EDC) forms that are specific to pediatric obesity research, ad hoc reporting capability, and pattern recognition tools that assist users in identifying the most effective treatment options.

In support of this initiative RemedyMD is seeking additional partners who have existing data that addresses the specific needs of pediatric obesity researchers. All institutions involved in comparative effectiveness research that are planning on submitting grant proposals for AHRQ funding are invited to visit: www.remedymd.com/cer100/pediatric_obesity.html

RemedyMD Resources:
Resource Kit for Comparative Effectiveness Research: www.remedymd.com/cer_kit
Ways to leverage Pediatric obesity Registry: www.remedymd.com/cer100/pediatric_obesity
Comparative Effectiveness Research: www.remedymd.com/cer_home
Disease Registry Software: www.remedymd.com/registries_home
Institute of Medicine’s Top 100 Priorities for CER: www.remedymd.com/cer_kit

About RemedyMD
RemedyMD® is the leading provider of specialized software applications, tools, and data necessary for comparative effectiveness research with more than 100 pre-built clinical, disease, and patient registry software applications. RemedyMD solutions are personalized to the institution, the clinical specialty, and to the individual provider’s preferences enabling researchers to identify new patterns, facilitate new discoveries, and improve medical outcomes. For more information, visit www.RemedyMD.com.

Press Contact:
Lane Peterson
RemedyMD
SALT LAKE CITY, US
801.733.3383
lpeterson@remedymd.com

http://www.RemedyMD.com